Endocrine Board Review (EBR) 2020 Test Item Writing

Thank you for your contributions to EBR 2021!

In recognition of the learning that occurs as a part of your authoring process, we are happy to offer CME credit and MOC points for your work.

Please complete a short online evaluation, which will provide you with a chance to reflect on your authoring experience and also help us ensure that this educational activity continues to meet your learning needs. Please click here to complete the survey, which should take you 3 minutes to complete, and claim your CME credit and MOC points.

Learning Objectives

Upon completion, participants will be able to:

  • Demonstrate enhanced knowledge in the field of endocrine physiology and pathophysiology.
  • Identify strengths and weaknesses of scientific test item writing.
  • Effectively communicate content and rationale for drafted cases during the peer-review process.
  • Integrate peer-review feedback into question writing.
  • Provide clear and concise learning objectives linked to a curriculum/content blueprint appropriate for the activity’s audience of learners.
  • Provide appropriate literature support for peers and learners to reinforce educational value through subsequent self-directed learning.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Other
Competency Area: 
Professionalism
Medical Knowledge
Interpersonal and Communication Skills
Topic Area: 
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 10.00 ABIM MOC
  • 10.00 AMA PRA Category 1 Credits
Course opens: 
02/01/2021
Course expires: 
12/31/2021
Rating: 
0

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Natalie Cusano, MD, MS, has served as a consultant to Shire/Takeda and Radius Pharmaceuticals and has served as a speaker for Shire/Takeda and Alexion.

Tobias Else, MD, has served as an advisory board member to Corcept Therapeutics, HRA Pharma and Merck, and his institution has received research support from Corcept Therapeutics, Merck and Strongbridge Biopharma.

Serge A. Jabbour, MD, has served as a consultant to AstraZeneca and Janssen, and his institution has received research support from the National Institutes of Health.

Sangeeta Kashyap, MD, has served as a consultant and co-investigator to GI Dynamics, and her institution has received research support from Janssen Pharmaceuticals.

Laurence Katznelson, MD, has served as a consultant and principal investigator to Chiasma and Camarus, and he has served as an advisory board member to Novo Nordisk.

Marie E. McDonnell, MD, has served as a trial event adjudicator for a trial conducted by Eisai.

Kathryn A. Martin, MD, has served as a physician editor for UpToDate.

The following faculty reported no relevant financial relationships: 
Frances J. Hayes, MB BCh, BAO; and Jacqueline Jonklaas, MD, PhD, MPH

Disclosure information for presenters is included in their individual recorded presentations.

The following staff reported no relevant financial relationships:
Abbie Young, MS, CGC, ELS(D); Michelle Klinke; Kelly Fischer; and Ankita Saxena

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 
Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Available Credit

  • 10.00 ABIM MOC
  • 10.00 AMA PRA Category 1 Credits